143 related articles for article (PubMed ID: 35008403)
1. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
Park JH; Jo JH; Jang SI; Chung MJ; Park JY; Bang S; Park SW; Song SY; Lee HS; Cho JH
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008403
[TBL] [Abstract][Full Text] [Related]
2. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
4. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
Pimenta JR; Ueda SKN; Peixoto RD
Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
6. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
Okada K; Uemura K; Okamoto W; Sumiyoshi T; Shintakuya R; Otsuka H; Serikawa M; Ishii Y; Arihiro K; Takahashi S
Clin J Gastroenterol; 2023 Apr; 16(2):283-288. PubMed ID: 36574187
[TBL] [Abstract][Full Text] [Related]
8. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
9. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
10. Circulating
van der Sijde F; Azmani Z; Besselink MG; Bonsing BA; de Groot JWB; Groot Koerkamp B; Haberkorn BCM; Homs MYV; van IJcken WFJ; Janssen QP; Lolkema MP; Luelmo SAC; Mekenkamp LJM; Mustafa DAM; van Schaik RHN; Wilmink JW; Vietsch EE; van Eijck CHJ
Ther Adv Med Oncol; 2021; 13():17588359211033704. PubMed ID: 34422118
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
13. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
14. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline
Yu S; Agarwal P; Mamtani R; Symecko H; Spielman K; O'Hara M; O'Dwyer PJ; Schneider C; Teitelbaum U; Nathanson KL; Domchek SM; Reiss KA
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100679
[TBL] [Abstract][Full Text] [Related]
16. Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
Meng F; Lu L; Tan Y; Duan Q; Lu H
Front Oncol; 2021; 11():757965. PubMed ID: 34671564
[TBL] [Abstract][Full Text] [Related]
17. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Sorscher S
Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
[TBL] [Abstract][Full Text] [Related]
20. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
